secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073421
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports FY 2025 net loss $299.6M; FDA priority review for atacicept PDUFA July 7, 2026
--------------------------------------------------------------------------------

- Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.
- Cash, equivalents, and marketable securities $714.6M as of Dec 31, 2025, expected to fund through atacicept launch.
- FDA granted priority review for atacicept BLA in IgA nephropathy; PDUFA date July 7, 2026.
- Completed $800M equity/debt financings; potential U.S. commercial launch mid-2026 if approved.
- Appointed James R. Meyers to Board; Phase 2 PIONEER basket trial results expected 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/0001193125-26-073421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/vera-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer